Ajanta Pharmaceuticals Moat Analysis: Score & Risks
Ajanta Pharmaceuticals Ltd.
A first-pass moat teardown of Ajanta Pharmaceuticals Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Ajanta Pharmaceuticals Ltd. scores 5.12 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“The investments of the past years in our field force, new therapies, new geographies, product pipeline, and people are entering their productive phase.”
“Almost 50% of our Branded Generics product basket consists of products which were launched for first time in that market ahead of the competition.”
“There will certainly be some operating leverage in new manufacturing facilities attributed to higher capacity utilisation, we expect our EBITDA margin to get normalised going forward.”
“Our first quarter performance has been satisfactory and it has been on the back of new product launches, market share gain and price increase.”
“CWIP includes cost incurred on corporate house under construction and is schedule to meet the annual rolling plan though there is delay as compared to the original plan due to delays in Government approval, pandemic and various other pediments outside of management control at various stages.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion